'No clinically meaningful impact' of switching from Enbrel to Sandoz biosimilar, study says

25 November 2016

Sandoz, the generics and biosimilars division of Swiss pharma giant Novartis (NOVN: VX), has announced new results from the EGALITY trial, a confirmatory clinical safety and efficacy study comparing its biosimilar version of etanercept to the originator product, Enbrel, in moderate to severe plaque psoriasis.

The new results not only offer further proof of the similarity in efficacy and safety between the biosimilar and reference product – this time after 52 weeks of treatment – but they also show that switching from one to the other has no clinically meaningful impact.

Enbrel is a biologic marketed by US biotech Amgen (Nasdaq: AMGN) and pharma giant Pfizer (NYSE: PFE) and is indicated in various inflammatory conditions including rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK